Spots Global Cancer Trial Database for phase 1 trial
Every month we try and update this database with for phase 1 trial cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
---|---|---|---|---|---|---|
The Pharmacokinetics and Safety of Single-dose and Parallel Comparisons in Patients With NSCLC Treated With JS001 | NCT03301688 | NSCLC | Toripalimab | 18 Years - 70 Years | Shanghai Junshi Bioscience Co., Ltd. | |
A Clinical Study of TAB006 in Patients With Previously Treated, Advanced Malignancies | NCT05253105 | Previously Trea... Malignancies | TAB006 Toripalimab | 18 Years - | Shanghai Junshi Bioscience Co., Ltd. | |
Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of Toripalimab for Patients With Recurrent Malignant Lymphoma | NCT03316144 | Malignant Lymph... | Toripalimab | 18 Years - 65 Years | Shanghai Junshi Bioscience Co., Ltd. | |
Safety, Tolerability and Pharmacokinetics of an Anti-PD-1 Monoclonal Antibody in Subjects With Advanced Malignancies | NCT03474640 | Advanced Malign... | Toripalimab, Re... | 18 Years - | Shanghai Junshi Bioscience Co., Ltd. | |
Safety, Tolerability and Pharmacokinetics of an Anti-PD-1 Monoclonal Antibody in Subjects With Advanced Malignancies | NCT03474640 | Advanced Malign... | Toripalimab, Re... | 18 Years - | Shanghai Junshi Bioscience Co., Ltd. | |
A Clinical Study of TAB006 in Patients With Previously Treated, Advanced Malignancies | NCT05253105 | Previously Trea... Malignancies | TAB006 Toripalimab | 18 Years - | Shanghai Junshi Bioscience Co., Ltd. | |
Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of Toripalimab for Patients With Recurrent Malignant Lymphoma | NCT03316144 | Malignant Lymph... | Toripalimab | 18 Years - 65 Years | Shanghai Junshi Bioscience Co., Ltd. | |
Safety, Tolerability and Pharmacokinetics of a Monoclonal Antibody Specific to B-and T-Lymphocyte Attenuator (BTLA) as Monotherapy and in Combination With an Anti-PD1 Monoclonal Antibody for Injection in Subjects With Advanced Malignancies | NCT04137900 | Advanced Unrese... Metastatic Soli... | TAB004 Toripalimab | 18 Years - | TopAlliance Biosciences | |
Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of an Anti-PD-1 mAb for Patients With Advanced Solid Tumors | NCT02836834 | Lymphoma Lung Cancer | JS001 | 18 Years - 65 Years | Shanghai Junshi Bioscience Co., Ltd. |